The landscape of medical treatment has been profoundly transformed by biologics—complex therapies like monoclonal antibodies, recombinant proteins, and nucleic acid-based solutions that target diseases with remarkable precision. Despite their groundbreaking impact, a significant challenge persists:
In the face of a potential extended federal government shutdown, U.S. healthcare providers are grappling with unprecedented challenges that could disrupt everything from patient care to financial stability, prompting urgent strategic planning. A recent flash survey conducted among 152 healthcare
In a landscape where rare diseases often struggle for attention and innovation, cutaneous T-cell lymphoma (CTCL)—encompassing mycosis fungoides (MF) and Sézary syndrome (SS)—stands as a stark reminder of unmet medical needs. With only a small fraction of cancer cases attributed to these conditions,
Today, we’re thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with a wealth of experience in research and development, and a deep passion for innovation in the industry. Ivan has been at the forefront of groundbreaking studies on the gut microbiome, particularly focusing on the
I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with a wealth of knowledge in tech and innovation within the industry. With his extensive background in research and development, Ivan brings a unique perspective to the intersection of technology and health. Today, we're
Imagine a future where life-saving medications and sustainable agricultural chemicals can be produced without the unpredictability and inefficiencies tied to living cells, a vision that is rapidly becoming reality through the innovative field of cell-free biomanufacturing. This transformative
The U.S. health care system is often touted as a bastion of free-market principles, yet a closer examination reveals a landscape riddled with contradictions that challenge this notion and expose deep-rooted issues. With annual health care spending surpassing $4 trillion, the stakes are enormous,
The biotechnology sector often rides a rollercoaster of high hopes and sharp setbacks, and few cases illustrate this better than the recent plunge in Exelixis’ stock value following the release of data from its STELLAR-303 trial. Focused on zanzalintinib, an experimental drug for metastatic
In a stunning turn of events that has captured national attention, a Los Angeles jury recently ordered Johnson & Johnson, a multinational giant in the healthcare industry, to pay a staggering $966 million to the family of Mae Moore, a California resident who tragically passed away in 2021 from
The startling reality that over 30% of adults may carry dangerous fat deposits deep within their abdomen or liver, even without visible signs of obesity, has sparked intense discussion in the medical community. This hidden fat, often undetectable through traditional measures like body mass index
